Table 1 Baseline Characteristics Comparison between Patients With and Without Diabetes Mellitus
Variables | Overall (N = 2287) | Without diabetes mellitus (N = 1115) | With diabetes mellitus (N = 1172) | P-value |
|---|---|---|---|---|
Age (years) | 63.7 ± 11.0 | 63.6 ± 11.6 | 63.7 ± 11.5 | 0.784 |
Male, n(%) | 1929 (84.4) | 948 (85.0) | 981 (83.7) | 0.385 |
Vital sign at admission | Â | Â | Â | Â |
Systolic blood pressure (mmHg) | 125.7 ± 20.7 | 124.6 ± 20.2 | 126.8 ± 21.1 | 0.014 |
Diastolic blood pressure (mmHg) | 74.4 ± 12.6 | 74.2 ± 12.5 | 74.6 ± 12.7 | 0.392 |
Heart rate (beat per minute) | 79.2 ± 15.1 | 77.6 ± 14.7 | 80.7 ± 15.3 | < 0.001 |
NYHA III-IV, n(%) | 582 (25.5) | 254 (22.8) | 328 (28.0) | 0.004 |
Reason for admission, n(%) | Â | Â | Â | Â |
Acute coronary syndrome | 1241 (54.3) | 644 (57.8) | 597 (50.9) | 0.001 |
Acute heart failure | 866 (37.9) | 375 (33.6) | 491 (41.9) | < 0.001 |
Laboratory at admission | Â | Â | Â | Â |
Hemoglobin (g/L) | 130.7 ± 20.5 | 132.3 ± 19.1 | 129.2 ± 21.6 | < 0.001 |
Total cholesterol (mmol/L) | 4.32 ± 1.27 | 4.35 ± 1.25 | 4.30 ± 1.28 | 0.372 |
Low-density lipoprotein cholesterol (mmol/L) | 2.81 ± 0.99 | 2.82 ± 0.99 | 2.80 ± 0.99 | 0.481 |
High-density lipoprotein cholesterol (mmol/L) | 0.96 ± 0.28 | 0.99 ± 0.30 | 0.93 ± 0.25 | < 0.001 |
Triglyceride (mmol/L) | 1.56 ± 1.06 | 1.45 ± 0.89 | 1.66 ± 1.18 | < 0.001 |
Lipoprotein(a) (mg/dL)* | 20.5 (10.1–43.0) | 21.7 (10.4–44.2) | 19.6 (9.8–40.8) | 0.091 |
Estimated glomerular filtration rate (ml/min/1.73m2)* | 74.6 (57.6–91.7) | 76.8 (60.9–93.1) | 71.9 (54.3–90.6) | < 0.001 |
Glycated hemoglobin A1c (%) | 6.8 ± 1.7 | 5.7 ± 0.5 | 7.8 ± 1.7 | < 0.001 |
Fasting blood glucose (mmol/L) | 6.22 ± 2.60 | 4.91 ± 0.75 | 7.41 ± 3.06 | < 0.001 |
High-sensitivity cardiac troponin-T (pg/mL)* | 37.1 (18.9-183.3) | 31.4 (16.5–159.0) | 41.2 (20.7-204.6) | < 0.001 |
 N-terminal B-type natriuretic peptide (pg/mL)* | 1568 (619–3827) | 1404 (522–3295) | 1772 (724–4260) | < 0.001 |
Echocardiographic index | Â | Â | Â | Â |
Left ventricular ejection fraction (%) | 36.3 ± 7.4 | 36.4 ± 7.4 | 36.3 ± 7.3 | 0.684 |
Coronary angiography, n(%) | Â | Â | Â | Â |
Left main | 584 (25.5) | 278 (24.9) | 306 (26.1) | 0.519 |
Three vessels | 490 (21.4) | 219 (19.6) | 271 (23.1) | 0.043 |
In-hospital percutaneous coronary intervention | 1566 (68.5) | 770 (69.1) | 796 (67.9) | 0.557 |
Comorbidities, n(%) | Â | Â | Â | Â |
Smoking status |  |  |  | < 0.001 |
Current | 465 (20.3) | 264 (23.7) | 201 (17.2) | Â |
Former | 380 (16.6) | 190 (17.0) | 190 (16.2) | Â |
Never | 1442 (63.1) | 661 (59.3) | 781 (66.6) | Â |
Hypertension | 1228 (53.7) | 550 (49.3) | 678 (57.9) | < 0.001 |
Chronic kidney disease | 620 (27.1) | 263 (23.6) | 357 (30.5) | < 0.001 |
Atrial fibrillation | 151 (6.6) | 67 (6.0) | 84 (7.2) | 0.265 |
Stroke | 185 (8.1) | 90 (8.1) | 95 (8.1) | 0.976 |
Myocardial infarction | 884 (38.7) | 432 (38.7) | 452 (38.6) | 0.930 |
Prior revascularization | 1267 (55.4) | 611 (54.8) | 656 (56.0) | 0.572 |
Malignant tumor | 32 (1.4) | 18 (1.6) | 14 (1.2) | 0.393 |
Medications at discharge, n(%) | Â | Â | Â | Â |
Dual anti-platelet | 1800 (78.7) | 872 (78.2) | 928 (79.2) | 0.569 |
Statins | 2162 (94.5) | 1065 (95.5) | 1097 (93.6) | 0.044 |
Betablocker | 1908 (83.4) | 924 (82.9) | 984 (84.0) | 0.484 |
Renin-angiotensin-system inhibitor | 1457 (63.7) | 720 (64.6) | 737 (62.9) | 0.401 |
Angiotensin receptor-neprilys inhibitor | 303 (13.3) | 144 (12.9) | 159 (13.6) | 0.646 |
Mineralocorticoid receptor antagonist | 1101 (48.2) | 508 (45.6) | 593 (50.6) | 0.015 |
Loop diuretic | 1057 (46.2) | 475 (42.6) | 582 (49.7) | 0.001 |
Digoxin | 136 (6.0) | 58 (5.2) | 78 (6.7) | 0.142 |
Calcium channel blocker | 275 (12.0) | 119 (10.7) | 156 (13.3) | 0.053 |
Sodium-dependent glucose transporters 2 inhibitor | 119 (5.2) | 2 (0.2) | 117 (10.0) | < 0.001 |
Oral anticoagulants | 530 (23.2) | 240 (21.5) | 290 (24.7) | 0.068 |